A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease

BioFactors

Volumn 9, Issue 2-4, 1999, Pages 267-272

  Shults, Clifford W ^a,b,e   Haas, Richard H ^a   Beal, M Flint ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); UBIDECARENONE; UBIQUINOL CYTOCHROME C REDUCTASE;

ARTICLE; CLINICAL ARTICLE; DOPAMINERGIC SYSTEM; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; HUMAN; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY CHAIN;

PARKINSONIA;

EID: 0033001416     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520090223     Document Type: Article

References (27)

1. 14C-dopamine in platelets; evidence for a generalized defect in Parkinson's disease, Neurology 25 (1975), 1-9.
2. 10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice, Brain Research 783 (1998), 109-114.
3. R. Benecke, P. Strümper and H. Weiss, Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes, Brain 116 (1993), 1451-1463.
4. D. Boullin and R. O'Brien, Accumulation of dopamine by blood platelets from normal subjects and parkinsonian patients under treatment with L-dopa, British Journal of Pharmacology 39 (1970), 779-788.
5. H.F. Bunn, Anemia associated with chronic disorders, in: Harrison's Principles of Internal Medicine, K.J. Isselbacher, E. Braunwald, J.D. Wilson, J.B. Martin, A.S. Fauci and D.L. Kasper, eds, McGraw-Hill, New York, 1994, pp. 1732-1734.
6. K. Chen, H.-F. Wu and J.C. Shin, The deduced amino acid sequences of human platelet and frontal cortex monoamine oxidase B are identical, Journal of Neurochemistry 61 (1993), 87-190.
7. J.T. Coyle and P. Puttfarcken, Oxidative stress, glutamate, and neurodegenerative disorders, Science 262 (1993), 689-695.
8. B. Frei, M.C. Kim and B.N. Ames, Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations, Proceedings of the National Academy of Sciences of the United States of America 87 (1990), 4879-4883.
9. W.R.G. Gibb, Neuropathology of Parkinson's disease and related disorders, in: Parkinson's Disease-Neurologic Clinics, J.M. Cedarbaum and S.T. Gancher, eds, Saunders, Philadelphia, 1992, pp. 567-593.
10. R. Haas, F. Nasirian, K. Nakano, D. Ward, M. Pay, R. Hill and C.W. Shults, Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease, Annals of Neurology 37 (1995), 714-722.
11. B. Halliwell and J.M.C. Gutteridge, Oxygen radicals and the nervous system, Trends in Neuroscience 8 (1985), 22-26.
12. M. Hashimoto, M. Yoshimoto, A. Sisk, L.J. Hsu, M. Sundsmo, A. Kittel, T. Saitoh, A. Miller and E. Maslilah, NACP a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation, Biochemical and Biophysical Research Communications 237 (1997), 611-616.
13. P. Jenner, A.H.V. Schapira and C.D. Marsden, New insights into the cause of Parkinson's disease, Neurology 42 (1992), 2241-2250.
14. D. Krige, M.T. Carroll, J.M. Cooper, C.D. Marsden and A.H.V. Schapira, Platelet mitochondrial function in Parkinson's disease, Annals of Neurology 32 (1992), 782-788.
15. J.W. Langston, P. Ballard, J.W. Tetrud and I. Irwin, Chronic parkinsonism in humans due to a produce of meperidine-analog synthesis, Science 219 (1983), 979-980.
16. A.N. Leiberman, Parkinson's disease, in: Current Therapy in Neurological Disease, R.T. Johnson, ed., 2nd edn, B.C. Decker, Philadelphia, 1987, pp. 217-220.
17. C.W. Olanow, A radical hypothesis for neurodegeneration, Trends in Neuroscience 16 (1993), 439-443.
18. W.D. Parker, Jr., S.J. Boyson and J.K. Parks, Abnormalities of the electron transport chain in idiopathic Parkinson's disease, Annals of Neurology 26 (1989), 719-723.
19. S. Przedborski, V. Jackson-Lewis, U. Muthane, H. Jiang, M. Ferreira, A.B. Naini and S. Fahn, Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity, Annals of Neurology 34 (1993), 715-723.
20. A.H.V. Schapira, Oxidative stress in Parkinson's disease, Neuropathology and Applied Neurobiology 21 (1995), 3-9.
21. A.H.V. Schapira, V.M. Mann, J.M. Cooper, D. Dexter, S.E. Daniel, P. Jenner, J.B. Clark and C.D. Marsden, Anatomic disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease, Journal of Neurochemistry 55 (1990), 2142-2145.
22. C.W. Shults, F. Nasirian, D.M. Ward, K. Nakano, M. Pay, L.R. Hill and R.H. Haas, Carbidopa/levodopa and selegiline do not affect platelet mitochondrial function in early parkinsonism, Neurology 45 (1995), 344-348.
23. 10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects, Annals of Neurology 42 (1997), 261-264.
24. 10 in parkinsonian patients, Neurology 50 (1998), 793-795.
25. T.P. Singer, N. Castagnoli, Jr., R.R. Ramsay and A.J. Trevor, Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Journal of Neurochemistry 49 (1987), 1-8.
26. R. Stocker, V.W. Bowry and B. Frei, Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does α-tocopherol, Proceedings of the National Academy of Sciences of the United States of America 88 (1991), 1646-1650.
27. H. Yoshino, Y. Nakagawa-Hattori, T. Kondo and Y. Mizuno, Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease, Journal of Neural Transmission 4 (1992), 27-34.